clinical trials and observational studies show efficacy and tolerability of adalimumab in the management of immune mediated inflammatory diseases.
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab / Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, Gionchetti P, Girolomoni G, Lapadula G, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Cimaz R. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - STAMPA. - 27:(2014), pp. 11-32. [10.1177/03946320140270S102]
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab
LIONETTI, PAOLO;CIMAZ, ROLANDO
2014
Abstract
clinical trials and observational studies show efficacy and tolerability of adalimumab in the management of immune mediated inflammatory diseases.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
